The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer
Open accessAbstract
FGFR3 is frequently activated by mutation in urothelial carcinoma (UC) and represents a potential target for therapy. In multiple myeloma, both over‐expression and mutation of FGFR3 contribute to tumour development. To define the population of UC patients who may benefit from FGFR‐targeted therapy, we assessed both mutation and receptor over‐expression in primary UCs from a population of new patients. Manual or laser capture microdissection was used to isolate pure tumour cell populations. Where present, non‐invasive and invasive components in the same section were microdissected. A screen of the region of the highest tumour stage in each sample yielded a mutation frequency of 42%. Mutations comprised 61 single and five double mutations, all in hotspot codons previously identified in UC. There was a significant association of mutation with low tumour grade and stage. Subsequently, non‐invasive areas from the 43 tumours with both non‐invasive and invasive components were analysed separately; 18 of these had mutation in at least one region, including nine with mutation in all regions examined, eight with mutation in only the non‐invasive component and one with different mutations in different regions. Of the eight with mutation in only the non‐invasive component, six were predicted to represent a single tumour and two showed morphological dissimilarity of fragments within the block, indicating the possible presence of distinct tumour clones. Immunohistochemistry showed over‐expression of FGFR3 protein in many tumours compared to normal bladder and ureteric controls. Increased expression was associated with mutation (85% of mutant tumours showed high‐level expression). Overall, 42% of tumours with no detectable mutation showed over‐expression, including many muscle‐invasive tumours. This may represent a non‐mutant subset of tumours in which FGFR3 signalling contributes to the transformed phenotype and which may benefit from FGFR‐targeted therapies. Copyright © 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histological Typing of Urinary Bladder Tumours
Mostofi, F. K., Davis, C. J., Sesterhenn, I. A., & Sobin, L. H. (1999) · Springer eBooks · doi:10.1007/978-3-642-59871-5 · Cited by 758
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 713
Urothelial tumorigenesis: a tale of divergent pathways
Wu, X.-R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1697 · Cited by 692
Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors
Billerey, C., Chopin, D., Aubriot-Lorton, M.-H., Ricol, D., Gil Diez de Medina, S., Van Rhijn, B., Bralet, M.-P., Lefrere-Belda, M.-A., Lahaye, J.-B., Abbou, C. C., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64665-2 · Cited by 498
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
Jebar, A. H., Hurst, C. D., Tomlinson, D. C., Johnston, C., Taylor, C. F., & Knowles, M. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208705 · Cited by 340
Self-citationHernández, S., López-Knowles, E., Lloreta, J., Kogevinas, M., Amorós, A., Tardón, A., Carrato, A., Serra, C., Malats, N., & Real, F. X. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1771 · Cited by 334
van Rhijn, B. W. G., Vis, A. N., van der Kwast, T. H., Kirkels, W. J., Radvanyi, F., Ooms, E. C. M., Chopin, D. K., Boevé, E. R., Jöbsis, A. C., & Zwarthoff, E. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.073 · Cited by 322
Chesi, M., Brents, L. A., Ely, S. A., Bais, C., Robbiani, D. F., Mesri, E. A., Kuehl, W. M., & Bergsagel, P. L. (2001) · Blood · doi:10.1182/blood.v97.3.729 · Cited by 289
Trudel, S., Li, Z. H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C., & Stewart, A. K. (2005) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 289
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
Knowles, M. A. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi310 · Cited by 248
Self-citation
Cited by
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Knowles, M. A., & Hurst, C. D. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3817 · Cited by 1,247
Self-citationSanli, O., Dobruch, J., Knowles, M. A., Burger, M., Alemozaffar, M., Nielsen, M. E., & Lotan, Y. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.22 · Cited by 814
Self-citationAdvances and challenges in targeting FGFR signalling in cancer
Babina, I. S., & Turner, N. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.8 · Cited by 799
Fibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 534
McConkey, D. J., Choi, W., Marquis, L., Martin, F., Williams, M. B., Shah, J., Svatek, R., Das, A., Adam, L., Kamat, A., et al. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9194-7 · Cited by 368
Metadata
- Authors
- Tomlinson, D., Baldo, O., Harnden, P., & Knowles, M.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2007-08-09
- Volume
- 213
- Issue
- 1
- Pages
- 91-98
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W1984145333
- Cited by
- 363
- References
- 26
- FWCI
- 17.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. https://app.cochat.ai/papers/10.1002/path.2207
- The paper
- Tomlinson, D., Baldo, O., Harnden, P., & Knowles, M. (2007). FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. The Journal of Pathology. https://doi.org/10.1002/path.2207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.